Argenx
ARGX
#491
Rank
NZ$85.71 B
Marketcap
NZ$1,371
Share price
0.81%
Change (1 day)
40.72%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

EPS for Argenx (ARGX)

EPS in 2026 (TTM): NZ$27.23

According to Argenx 's latest financial reports the company's current EPS (TTM) is NZ$26.96. In 2024 the company made an earnings per share (EPS) of NZ$23.74 an increase over its 2023 EPS that were of NZ-$8.80.

EPS history for Argenx from 2011 to 2026

Annual EPS

Year EPS Change
2026 (TTM)NZ$27.23
2024NZ$23.74-369.77%
2023NZ-$8.80-60.46%
2022NZ-$22.2563.33%
2021NZ-$13.63-40.37%
2020NZ-$22.85183.47%
2019NZ-$8.06123.09%
2018NZ-$3.6154.93%
2017NZ-$2.3314.07%
2016NZ-$2.0413.05%
2015NZ-$1.81-36.34%
2014NZ-$2.84209.04%
2013NZ-$0.92-33.99%
2012NZ-$1.39185.59%
2011NZ-$0.49